Express News | Fosun Pharmaceuticals: The holding subsidiary received approval for the registration of cycloserine capsules
復星醫藥:二零二三年年報
A record high! Fosun Pharmaceutical (02196) was selected as one of the top 20 global pharmaceutical companies in terms of pipeline size
For the third year in a row, Fosun Pharmaceutical (02196) was selected as one of the top 25 pharmaceutical companies in the world, ranking 17th, up 7 places from the previous year.
Fosun Pharmaceutical (02196.HK): Investment funds participating in the establishment completed private equity fund filing
Gelonghui, April 22, 丨 Fosun Pharmaceutical (02196.HK) announced that on March 30, 2023, the company's holding subsidiary/enterprise Shanghai Fuyu Shengjian Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as “Fuyu Shengjian”), Ningbo Fuying Investment Co., Ltd. (hereinafter referred to as “Ningbo Fuying”) and other 2 investors signed the “Anji Fuyu Chengxiang Venture Capital Partnership (Limited Partnership) Limited Partnership” with other investors to jointly fund the establishment of Anji Fucheng Yuxiang Venture Capital Partnership (Limited Partnership) “Equipment Fund”); same day, Company holding subsidiaries/corporate recovery
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
China's drug regulator granted clinical trial approval to a Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) subsidiary for its HLX53 combination with slulimumab and bevacizumab injections
Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year
Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.
Fosun Pharmaceutical (02196.HK) held a board meeting on April 29 to consider and approve the first quarter results
Gelonghui, April 17, 丨 Fosun Pharmaceutical (02196.HK) announced that it will hold a board meeting on April 29, 2024 (Monday) to consider, approve and publish the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024.
復星醫藥:董事會會議日期
Fosun Pharmaceutical (600196.SH): Holding subsidiary Fuhong Hanlin (02696) was approved for drug clinical trials
Fosun Pharmaceutical (600196.SH) announced that Shanghai Fuhong Hanlin Biotechnology Co., Ltd., a holding subsidiary of the company...
Express News | Fosun Pharmaceutical: The holding subsidiary received the registration application for sodium phosphonate injection
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Fosun Pharmaceutical (02196.HK): Fuhong Hanlin plans to guarantee Hanlin Pharmaceutical's financing debt with a principal amount not exceeding 150 million yuan from China Construction Bank
Fosun Pharmaceutical (02196.HK) announced that on April 9, 2024, the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. (“Fuhong Hanlin”) and its holding subsidiaries Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd. (“Hanlin Pharmaceuticals”) and Shanghai Fuhong Hanlin Biomedical Co., Ltd. (“Hanlin Pharmaceuticals”) signed a “Credit Agreement” with China Merchants Bank Co., Ltd. Shanghai Branch (“China Merchants Bank”). Is it OK to jointly apply for principal amount from China Merchants Bank Over the equivalent value of RMB 200 million
Research Report: Zheshang Securities: Maintaining Fosun Pharmaceuticals' “Buy” Rating, Optimistic About the Company's International Implementation
Gelonghui, April 9 | According to the Zhejiang Securities Research Report, Fosun Pharmaceutical (600196.SH)'s revenue in 2023 increased by about 12.43% year on year. Among them, revenue from key varieties such as Hans form, injectable trastuzumab, and Sukexin maintained rapid growth. I am optimistic that the company will become one of the few domestic pharmaceutical companies with the ability to commercialize innovative drugs internationally, and I am also optimistic about the company's international implementation. Considering that the impact of the company's 2023 COVID-related products and asset impairment, dollar interest rate hikes, etc. on financial expenses exceeded our previous expectations, the company's profit for 2023-2025 was lowered
Fosun Pharmaceutical (600196): Optimistic about the continued advancement of internationalization & innovation
The main investment points exclude the anti-epidemic product base, and the main business continues to grow rapidly, and I am optimistic that internationalization and innovation will continue to be realized. Performance: Excluding the anti-epidemic product base, 2023 revenue continues to be stable The company discloses 2023 performance: Achieved revenue in 2023
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remain
Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remains steady; 2) maintaining 25%-30% share of device diagnosis and medical services; 3) when the types of research progressed smoothly and innovation and transformation were underway. (Mainichi Keizai Shimbun)
Selected announcements | China's non-ferrous mining industry plans to sell up to 163 million shares at a discount of about 13.54%; Longyuan Electric Power's power generation will increase by about 10% during the year
China's net profit for the first quarter was 2,308 billion yuan, up 0.33% year on year; Qiutai Technology sold about 368.39 million mobile phone camera modules in March, up 31.8% from month to month, down 1.7% year on year.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs
China's medical products administrator accepted the new drug applications of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) unit Fosun Pharmaceutical Industrial Development for the treatment of
No Data